HopeStage
Back to all studies
CompletedNCT04723147

Carbidopa-levodopa for depression with loss of interest

About this titleRead the official source — NCT04723147
Medication studyAges 25–55United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 25 years to 55 years. Other eligibility criteria applied.

Listed locations
AtlantaSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 29, 2021
Recruitment status
Completed
Enrollment listed in the registry
19
Sponsor
Emory University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 25 Years to 55 Years
Official registry ID
NCT04723147
Official title
Show the full official title

Dopaminergic Therapy for Inflammation-Related Anhedonia in Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Atlanta

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Emory University, a university.

Did this study involve medication?

Yes. The study involved medication, including Carbidopa Levodopa and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 25 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies